PFK1 Cancer Research Results

PFK1, Phosphofructokinase-1: Click to Expand ⟱
Source:
Type:
Phosphofructokinase-1 (PFK1) is a key regulatory enzyme in glycolysis that catalyzes the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate.
– As a rate-limiting enzyme in glycolysis, PFK1 is subject to complex regulation through allosteric effectors including ATP, AMP, and fructose-2,6-bisphosphate.
• Metabolic Control:
–PFK1 activity is central to controlling the pace of glycolysis, thereby influencing energy production and intermediary metabolite supply.
– In highly proliferative cells or cells under growth conditions, increased glycolytic flux (and, by extension, PFK1 activity) supports the biosynthetic demands of cell division.

– Many tumors (including breast, colorectal, and lung cancers) have been reported to have increased PFK1 expression/activity relative to normal tissues.
– High glycolytic flux, driven partly by enhanced PFK1, supports rapid cell proliferation and survival in the nutrient/stress-challenged tumor microenvironment.

Inhibitors:(typically glycolysis is targeted more broadly)
-Citrate
-Hydrogen ions (pH) – Acidic conditions can have inhibitory effects.
-3PO: inhibits PFKFB3, thereby indirectly reducing PFK1 activity.
-Resveratrol can downregulate glycolytic flux in cancer cells, which may indirectly affect PFK1 activity.
- FMDs offer an indirect strategy to modulate cancer metabolism by broadly reducing glycolysis. Their impact on PFK1 is likely part of a complex network of metabolic adaptations rather than a direct inhibitory effect.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
2293- Ba,    Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling
- in-vitro, Nor, MH-S - in-vivo, NA, NA
*Hif1a↓, *Glycolysis↓, *Inflam↓, *HK2↓, *PFK1↓, *PKM2↓,
2421- PB,    Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway
- in-vitro, HCC, HCCLM3 - in-vivo, NA, NA - in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vitro, Nor, L02
Glycolysis↓, Apoptosis↑, TumCP↓, lactateProd↓, GlucoseCon↓, HK2↓, ChemoSen↑, *toxicity↓, cMyc↓, PFK1↓, LDHA↓, cMyc↓, ChemoSen↑,
2419- SK,    Regulation of glycolysis and the Warburg effect in wound healing
- in-vivo, Nor, NA
Glycolysis↓, GLUT1↓, GLUT3↓, HK2↓, HK1↓, PFK1↓, PFK2↓, PKM2↓, lactateProd↓, GlucoseCon↓,
3144- VitC,    Some characteristics of Rabbit muscle phosphofructokinase-1 inhibition by ascorbate
- in-vitro, Nor, NA
PFK1↓, LDH↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HK1↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   GlucoseCon↓, 2,   Glycolysis↓, 2,   HK2↓, 2,   lactateProd↓, 2,   LDH↓, 1,   LDHA↓, 1,   PFK1↓, 3,   PFK2↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Migration ⓘ

TumCP↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT3↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   HK2↓, 1,   PFK1↓, 1,   PKM2↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 7

Scientific Paper Hit Count for: PFK1, Phosphofructokinase-1
1 Baicalein
1 Phenylbutyrate
1 Shikonin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:988  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page